Trial Profile
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary) ; Hydrochlorothiazide
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms BP CRUSH
- Sponsors Daiichi Sankyo Inc
- 03 May 2010 Preliminary results were presented during the late breaker poster session of the American Society of Hypertension (ASH) annual meeting, according to a Daiichi Sankyo media release.
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.